Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China.
Int J Rheum Dis. 2019 Sep;22(9):1775-1781. doi: 10.1111/1756-185X.13671. Epub 2019 Jul 31.
This study aimed to retrospectively describe 15 new primary Sjögren's syndrome-pulmonary arterial hypertension (pSS-PAH) cases confirmed by right heart catheterization (RHC). Demographic and clinical characteristics were analyzed and risk factors for PAH in pSS were explored.
We retrospectively described 15 new pSS-PAH cases confirmed by RHC referred to our institution between January 2013 and March 2018. We present PAH and pSS characteristics, hemodynamic evaluations, medical management, and outcomes. A matched case control study was carried out to determine the risk factors of PAH in pSS compared with pSS-non-PAH patients.
All patients were female with a mean age at PAH diagnosis of 52.9 ± 14.6 years. The delay between the first symptom and PAH diagnosis was 18.7 ± 19.7 months. The most common primary manifestation at PAH onset was exertional dyspnea (13/15). At diagnosis of PAH, PAH was severe with a mean pulmonary artery pressure of 48.8 ± 13.7 mm Hg (range, 27-72 mm Hg) and a mean cardiac index of 2.3 ± 0.6 L/min/m (range, 1.47-3.41 L/min/m ). Compared with the pSS-PAH without pericardial effusion, pSS-PAH with pericardial effusion had larger right arterial (53 [45-56.75] vs 38 [35.5-46.5], P = .018) and right ventricular sizes (47 [42.75-51.25] vs 36 [32.5-41], P = .007). Compared with the pSS non-PAH group, we identified 2 risk factors for PAH in pSS: pericardial effusion (odds ratio [OR] [95% CI], 14.29 [1.14-166.67], P = .039) and liver involvement (OR [95% CI], 14.71 [1.14-166.67], P = .035).
For pSS patients, PAH can be the first manifestation. We believe that systemic evaluation, especially in patients with pericardial effusion and liver involvement, is important to identify high-risk patients for PAH, improving their prognosis.
本研究旨在通过右心导管检查(RHC)回顾性描述 15 例新确诊的原发性干燥综合征-肺动脉高压(pSS-PAH)患者。分析人口统计学和临床特征,并探讨 pSS 中肺动脉高压的危险因素。
我们回顾性描述了 2013 年 1 月至 2018 年 3 月期间我院收治的 15 例经 RHC 确诊的新 pSS-PAH 病例。我们介绍了 PAH 和 pSS 的特征、血流动力学评估、药物治疗和结果。我们进行了匹配的病例对照研究,以确定与 pSS 非 PAH 患者相比,pSS 中 PAH 的危险因素。
所有患者均为女性,PAH 诊断时的平均年龄为 52.9±14.6 岁。从首发症状到 PAH 诊断的延迟时间为 18.7±19.7 个月。PAH 起始时最常见的原发性表现为运动性呼吸困难(13/15)。在 PAH 诊断时,肺动脉压严重,平均为 48.8±13.7mmHg(范围 27-72mmHg),平均心指数为 2.3±0.6L/min/m(范围 1.47-3.41L/min/m)。与无心包积液的 pSS-PAH 相比,有心包积液的 pSS-PAH 患者的右心房(53[45-56.75]vs 38[35.5-46.5],P=0.018)和右心室大小(47[42.75-51.25]vs 36[32.5-41],P=0.007)更大。与 pSS 非 PAH 组相比,我们确定了 pSS 中 PAH 的 2 个危险因素:心包积液(比值比[OR] [95%CI],14.29 [1.14-166.67],P=0.039)和肝脏受累(OR [95%CI],14.71 [1.14-166.67],P=0.035)。
对于 pSS 患者,PAH 可能是首发表现。我们认为系统评估,特别是在有心包积液和肝脏受累的患者中,对于识别 PAH 的高危患者,改善其预后非常重要。